Lung Cancer News

An analysis of global online conversations among health care professionals on social media in February showed an overarching sense of enthusiasm about FDA approval of the first cellular therapy to treat unresectable or metastatic melanoma.

Arya Amini, MD, still remembers sitting on the steps outside of his dean’s office at University of California, Irvine, more than a decade ago, prepared to race inside in case he did not get matched with a radiation oncology residency.

The FDA on Friday approved Rybrevant in combination with chemotherapy as the first first-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations, Johnson & Johnson announced.

Medicare recipients with various cancer types had more frequent surgical complications when they also had at least one behavioral health disorder, according to study results published in Journal of the American College of Surgeons.

Black patients and those with interstitial fibrosis or advanced-stage disease had a higher risk for developing clinically detectable postoperative venous thromboembolism after pulmonary resection for lung cancer, study results showed.

To help individuals who undergo cancer treatment lead healthier lives, Stacyann Bailey, PhD, has one overarching professional mission — to prevent bones from breaking.

More than 130,000 cancer cases went undiagnosed during the first 10 months of the COVID-19 pandemic, researchers estimated in a cross-sectional analysis published in JAMA Oncology.

Most oncologists treating non-small cell lung cancer reported more research into immunotherapy treatments, patients with comorbidities and biomarker testing will be vital to improving care, according to results of a nationwide survey.

The FDA approved osimertinib plus platinum-based chemotherapy for certain adults with locally advanced or metastatic non-small cell lung cancer.

Limiting eligibility criteria, recruiting trusted community messengers and reducing financial burdens can help improve diversity of clinical trial enrollees, a panel of professionals said during a Friends of Cancer Research webinar.